At the international scientific congress ObesityWeek® held late last year in Atlanta, United States, Novo Nordisk presented findings from a real-world analysis of grocery spending data from more than 200,000 households.[1] The analysis found that households with at least one person using Novo Nordisk's GLP‑1 RA for weight management showed a year-on-year reduction in overall grocery spending compared with households not using similar medicines—most notably in purchases of alcohol and tobacco/cig